Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02082210 · ClinicalTrials.gov registry record · Phase 1
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 97
- Enrollment target
NCT02082210 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 97 participants.
The verdict
NCT02082210, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 97 participants
- Enrollment target
Study Summary
The purpose of this study is to find a recommended schedule and dose range for Emibetuzumab when given with ramucirumab that may be safely given to participants with cancer. In Part A of this study, escalating doses of Emibetuzumab will be given in combination with a fixed dose of ramucirumab to evaluate the safety of the combination. After a recommended schedule and dose range of Emibetuzumab and ramucirumab has been established, Part B of the study will confirm safety and to see how well certain tumors respond to the combination of study drugs. The average amount of time on study is expected to be about 6 months.
Interventions
- DRUG Ramucirumab
- DRUG Emibetuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 97 participants |
| Start Date | 2014-03-07 |
| Est. Completion | 2018-01-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02082210
The ClinicalTrials.gov registry entry for NCT02082210 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ramucirumab is the first listed.
NCT02082210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02082210 about?
NCT02082210 is a clinical study titled "A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer". The purpose of this study is to find a recommended schedule and dose range for Emibetuzumab when given with ramucirumab that may be safely given to participants with cancer. In Part A of this study, escalating doses of Emibetuzumab will be given in combination with a fixed dose of ramucirumab to eva...
What is the current status of trial NCT02082210?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2014-03-07. Estimated completion is 2018-01-24.
What interventions are being tested in trial NCT02082210?
The interventions under investigation include: Ramucirumab (DRUG), Emibetuzumab (DRUG).
Who is sponsoring clinical trial NCT02082210?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.